Evolent Health (EVH) Q2 2026 Earnings Call Transcript
Evolent Health (EVH) reported Q2 2026 revenue of $652.5M versus $444.3M a year earlier, citing the Highmark contract launch. Net loss attributable to common shareholders was $28.4M. Adjusted EBITDA was $28.1M. Full-year 2026 revenue guidance was raised to $2.6B-$2.7B and adjusted EBITDA to $120M-$135M. 2027 revenue growth is expected to exceed 25%.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised 2026 guidance ranges, the 2027 growth and adjusted EBITDA outlook, and the planned oncology Performance Suite partnership launch by Dec. 2026, all weighed against explicit membership and margin headwinds.
Market read
Guidance upgrades and a large oncology partnership projection are likely to drive re-rating, while margin and membership risks may cap upside and increase volatility.
What to watch
Operating cash flow was impacted by about $20M of onetime items, and management flagged membership pressure through 2027, which could pressure near-term leverage and valuation even with guidance raises.
Background
Evolent’s Q2 2026 call centers on scaling its AI authorization platform and expanding Performance Suite contracts, especially tied to the Highmark launch.
Ticker impact
Evolent reported Q2 revenue of $652.5M, raised 2026 revenue guidance to $2.6B-$2.7B, and guided 2026 adjusted EBITDA to $120M-$135M.
Near-term bias positive on guidance raise and 2027 growth outlook, with volatility risk if investors focus on margin compression and membership headwinds.
The call includes multiple forward-looking datapoints (raised 2026 ranges, 2027 growth >25%, oncology partnership launch by Dec. 2026) plus explicit risk framing (Medicaid/exchange declines, operating cash flow timing, medical expense ratio increase).
Market effects
Reinforces demand for AI-enabled prior authorization and capitated specialty care management, potentially supporting sentiment toward managed-care tech and value-based specialty platforms.
Blue Cross and Highmark/Aetna partnership execution signals continued payer investment in specialty care management across US regional plans.
Limited direct global impact; primarily US payer-provider operations and reimbursement dynamics.
Counterpoint
The revenue growth mix shift toward higher-growth, lower-margin Performance Suite plus rising medical expense ratio could mean the EBITDA improvement is less durable than investors expect.
Key entities
- companyEvolent Health, Inc.
Subject of the earnings call transcript; reported Q2 results, raised 2026 guidance, and outlined 2027 growth and AI platform scale.
- executiveSeth Blackley
CEO who described Q2 as a tipping point for AI scale and discussed 2027 growth absorbing membership declines.
- executiveMario Ramos
CFO who highlighted Medicaid/exchange membership pressure and cash flow impacts from onetime items.
- customer/partnerHighmark
Payer partner whose May 1, 2026 launch drove higher Performance Suite membership and revenue contribution in Q2 and expected Q3.
- customer/partnerAetna
Payer referenced for clinical engagement and claims performance trending in line with expectations.
